|Day Low/High||90.05 / 91.70|
|52 Wk Low/High||62.55 / 97.86|
But the 3% drop in the sector yesterday is clearly an overreaction to Trump's comments.
Here is a look at some stocks that are poised for excellent dividend returns in 2017.
We touched briefly on housing in our first post this morning. There are still some cheap home-building stocks if the housing market continues to improve, which I expect as I believe economic growth will pick up in 2017. I have done well with this se...
Overall, the next move for ABBV looks like it will be to the upside.
Check out these 15 stocks that boast solid dividend yields and are growing earnings.
Today there was a virtual vacuum of good news in the stock market.
We have to ask: where is the cash flow to pay off the debt, if any important prices are rolled back?
Shares of AbbVie were lower Friday after posting disappointing third-quarter revenue.
McKesson's disappointing earnings report ignited a selloff in health care stocks, and Jim Cramer says investors are questioning the sector's future.
With Clinton apparently headed for victory, worries about her being a threat to health-care stocks have peaked.
If and when interest rates go up, this basket of stocks should continue to do well.
Small biotech tanked on weak earnings, but still seems promising.
RBC Capital analysts say splitting the company into two distinct businesses would free 'trapped value' on drug treatments.
Stocks secure robust gains after the latest labor market snapshot breezes past expectations.
Rarely do investors get to buy these types of quality businesses at such discounted prices.
The sector seems to be rebounding after tumbling by more than 40%.
The bifurcation can be seen just by looking at Apple's recent results.
Shares of AbbVie were up Friday after the company reported a big jump in revenue.
Consider raising your sell stop protection to a close below $61.
The Anheuser-Busch InBev and SABMiller deal is another step closer to completion.
It's too cheap for a biotech giant with years of patent protection for key products and great cash flow.